Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 194,792
  • Shares Outstanding, K 44,677
  • Annual Sales, $ 490 K
  • Annual Income, $ -41,440 K
  • 60-Month Beta 1.93
  • Price/Sales 398.25
  • Price/Cash Flow N/A
  • Price/Book 2.80
Trade CRDF with:

Options Overview Details

View History
  • Implied Volatility 157.32% ( +2.70%)
  • Historical Volatility 106.28%
  • IV Percentile 35%
  • IV Rank 15.77%
  • IV High 658.16% on 10/03/23
  • IV Low 63.55% on 05/24/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 30
  • Volume Avg (30-Day) 933
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 16,272
  • Open Int (30-Day) 18,094

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.25
  • Number of Estimates 4
  • High Estimate -0.23
  • Low Estimate -0.27
  • Prior Year -0.25
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.20 +3.81%
on 04/16/24
6.42 -32.09%
on 03/25/24
-1.49 (-25.47%)
since 03/22/24
3-Month
1.44 +202.78%
on 02/05/24
6.42 -32.09%
on 03/25/24
+2.83 (+184.97%)
since 01/23/24
52-Week
0.94 +363.83%
on 11/10/23
6.42 -32.09%
on 03/25/24
+2.88 (+194.59%)
since 04/21/23

Most Recent Stories

More News
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END

ONCY : 1.0600 (+1.92%)
ONC.TO : 1.46 (unch)
CRDF : 4.30 (-1.38%)
LLY : 736.69 (+0.73%)
ABBV : 169.03 (+0.68%)
LIPO : 0.7300 (+1.39%)
Nasdaq Futures Climb as Bond Yields Retreat From Decade Highs, Micron Earnings on Tap

December Nasdaq 100 E-Mini futures (NQZ23) are trending up +0.44% this morning as U.S. Treasury yields slipped from decade highs, while investors braced for a new round of economic data as well as an earnings...

NQZ23 : 16,530.23s (-0.07%)
CTAS : 667.49 (+0.37%)
AAPL : 166.25 (+0.25%)
GOOGL : 157.93 (+1.06%)
AMZN : 176.35 (-0.50%)
DKNG : 41.38 (+2.05%)
MU : 110.74 (+1.48%)
PAYX : 121.73 (+0.41%)
JEF : 44.05 (+1.19%)
HMB.S.DX : 180.500 (+3.57%)
COST : 717.00 (+0.22%)
CHPT : 1.3900 (+2.21%)
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical...

CRDF : 4.30 (-1.38%)
Cardiff Oncology to Present at Upcoming Investor Conferences in September

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug...

CRDF : 4.30 (-1.38%)
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug...

CRDF : 4.30 (-1.38%)
Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year’s End

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:CRDF),(NASDAQ:BDRX),(NASDAQ:DRUG),(NYSE:LLY) EQNX::TICKER_END

CRDF : 4.30 (-1.38%)
BDRX : 0.7651 (+0.01%)
DRUG : 1.1200 (unch)
LLY : 736.69 (+0.73%)
PTN : 1.7400 (+1.16%)
Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year's End

/PRNewswire/ -- About 9.4% of the world population is aged 65 or above. Older people typically consume more medicines than the people in other age group...

PTN : 1.7400 (+1.16%)
CRDF : 4.30 (-1.38%)
BDRX : 0.7651 (+0.01%)
DRUG : 1.1200 (unch)
LLY : 736.69 (+0.73%)
Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

- Advance to first-line RAS-mutated mCRC follows the strong signal from new clinical and preclinical data, and agreement with FDA - - First-line mCRC...

CRDF : 4.30 (-1.38%)
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug...

CRDF : 4.30 (-1.38%)
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug...

CRDF : 4.30 (-1.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of...

See More

Key Turning Points

3rd Resistance Point 4.72
2nd Resistance Point 4.61
1st Resistance Point 4.48
Last Price 4.30
1st Support Level 4.24
2nd Support Level 4.13
3rd Support Level 4.00

See More

52-Week High 6.42
Fibonacci 61.8% 4.33
Last Price 4.30
Fibonacci 50% 3.68
Fibonacci 38.2% 3.03
52-Week Low 0.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar